Skip to main content

Search

Clear
Filter by Type
Filter by Topics
Filter by Symptoms & Conditions
Filter by Year
Do You Use the APTA Learning Center? Read This

Oct 14, 2022/News

APTA's popular continuing education resource is making a big change, and it could affect you.

APTA President's Podcast: Address to the 2022 APTA House of Delegates

Sep 14, 2022/Podcast

Hear what the APTA President had to say about where the profession is, and what it will take to pursue our full potential.

Prior Authorization: 5 Ways CMS Changes Could Open up Future Possibilities

Mar 7, 2023/Article

The proposed rules would help ease immediate burdens, but there are also long-game reasons to voice your support by March 13.

Jim McKillip, 'a Force for the Profession,' Honored With Room at APTA HQ

Dec 11, 2023/News

McKillip helped establish fee schedules in California, was a founder of APTA Private Practice, and served as PTPAC's first president.

PTJ Author Interview With Richard Shields: The Jules M. Rothstein Golden Pen Award for Scientific Writing

Nov 26, 2024/Podcast

Editor-in-Chief Steven George, PT, PhD, FAPTA, talks with Richard Shields PT, PhD, FAPTA, about winning the 2024 Jules M. Rothstein Golden Pen Award for Scientific Writing.

Defining Moment: The Glue Holding It All Together

Nov 5, 2024/Podcast

Allen Wicken, PT, MSPT, a longtime physical therapist and APTA member, reflects on the interconnectedness of the profession.

Defining Moment: Healing the Little Brain

Apr 29, 2025/Podcast

In the April 2025 issue of APTA Magazine, Elizabeth Pimentel, PT, MA, recalls a memorable patient and her struggles to make peace with the patient’s untimely death.

Survey: Many PTs Encounter Barriers to Finding, Implementing Evidence

May 1, 2023/Review

The survey was conducted in Brazil — could the same be true in the U.S.? APTA member resources can help eliminate EBP obstacles.

Hand Held Myometry/Dynamometry

Mar 1, 2025/Test & Measure

Hand Held Myometry/Dynamometry

Rivermead Mobility Index for Multiple Sclerosis (MS)

Sep 12, 2013/Test & Measure

Target population: People with multiple sclerosis (MS).